Drugs / allo-APZ2-PAOD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03339973 | Mar 2018 → May 2020 | peripheral arterial occlusive disease 1 | RHEACELL GmbH & Co. KG | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allo-APZ2-PAOD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03339973 ↗ |
| Route | Intramuscular | “allo-APZ2-PAOD administered intramuscularly into an affected lower leg” NCT03339973 ↗ |